A study of the combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer / 中华外科杂志
Chinese Journal of Surgery
; (12): 745-747, 2006.
Article
em Zh
| WPRIM
| ID: wpr-300619
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the clinical efficacy and toxicity of vinorelbine (N) and epirubicin (E) as the neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer (LABC).</p><p><b>METHODS</b>From September 2001 to December 2004, 158 patients with LABC were treated with NE chemotherapy before operation. Neoadjuvant chemotherapy containing vinorelbine (N), 25 mg/m(2) (days 1 and 8) and epirubicin (E), 60 mg/m(2) (days 1) was administered every 3 weeks for three cycles before local treatment.</p><p><b>RESULTS</b>Response in the breast: the clinical objective response was 81.6% [23.4% (37/158) cCR and 58.2% (92/158) PR], 16.5% (26/158) SD and 1.9% (3/158) PD. Pathological complete response was found in 29 cases (18.3%). Eighteen cases (26.5%) who have positive FNA result in the axillary lymphnode before chemotherapy showed negative result in the surgery specimen. The most common toxicities were neutropenia, alopecia and nausea/vomiting. Neutropenia grade 3 - 4 was reported in 111 patients (70.3%) and there was no toxic deaths.</p><p><b>CONCLUSIONS</b>The combination of vinorelbine and epirubicin is a very active and well-tolerated regimen as neoadjuvant chemotherapy for the LABC.</p>
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Patologia
/
Vimblastina
/
Neoplasias da Mama
/
Esquema de Medicação
/
Epirubicina
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Resultado do Tratamento
/
Quimioterapia Adjuvante
/
Usos Terapêuticos
/
Tratamento Farmacológico
Limite:
Adult
/
Aged
/
Female
/
Humans
Idioma:
Zh
Revista:
Chinese Journal of Surgery
Ano de publicação:
2006
Tipo de documento:
Article